Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Heynemann

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
Der Urologe. Ausg. A|October 14, 2015
[The 22nd annual meeting of the working group for kidney transplantation of the German Society of Urology in Rostock]J Putz, M Giessing, P Fornara, et al.
British Journal of Cancer|March 10, 2005
Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)J Atzpodien, E Schmitt, U Gertenbach, et al.
Der Urologe. Ausg. A|December 26, 2015
[Prostate biopsy: Procedure in the clinical routine]T Enzmann, T Tokas, K Korte, et al.
British Journal of Cancer|August 16, 2006
Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)J Atzpodien, H Kirchner, U Rebmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2004
Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)J Atzpodien, H Kirchner, U Jonas, et al.
Folia Biologica|December 19, 2003
Efficacy and safety of inhaled recombinant interleukin-2 in high-risk renal cell cancer patients compared with systemic interleukin-2: an outcome studyE Huland, A Burger, J Fleischer, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Der Urologe. Ausg. A|October 14, 2015
[The 22nd annual meeting of the working group for kidney transplantation of the German Society of Urology in Rostock]J Putz, M Giessing, P Fornara, et al.
British Journal of Cancer|March 10, 2005
Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)J Atzpodien, E Schmitt, U Gertenbach, et al.
Der Urologe. Ausg. A|December 26, 2015
[Prostate biopsy: Procedure in the clinical routine]T Enzmann, T Tokas, K Korte, et al.
British Journal of Cancer|August 16, 2006
Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)J Atzpodien, H Kirchner, U Rebmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2004
Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)J Atzpodien, H Kirchner, U Jonas, et al.
Folia Biologica|December 19, 2003
Efficacy and safety of inhaled recombinant interleukin-2 in high-risk renal cell cancer patients compared with systemic interleukin-2: an outcome studyE Huland, A Burger, J Fleischer, et al.
Pageof 6